Empagliflozin improves cognitive impairment in frail diabetics with HFpEF: Study Medha Baranwal1 April 2022 10:45 AM ISTItaly: SGLT2 inhibitor empagliflozin improves cognitive and physical impairment in frail older adults with type 2 diabetes and heart failure with...
28/February/2022 Top Medical Bulletin Dr. Nandita Mohan28 Feb 2022 6:45 PM ISTHere are top medical stories for todayGlucose Variability During Early Course Of Acute Pancreatitis Can Predict New-Onset Of Diabetes Diabetes is a...
25/February/2022 Top Medical Bulletin Dr. Nandita Mohan25 Feb 2022 6:51 PM ISTHere are today's top medical stories Is French fried potato consumption Related to Adverse Health Outcomes?Fries is a most consumed junk food all...
SGLT2 inhibitor dapagliflozin may prevent cardiovascular complications in type 1 diabetes: Study Medha Baranwal23 Feb 2022 9:45 AM ISTBudapest, Hungary: Recent data published in PLOS One supports the preventive and protective role of SGLT2 inhibitors in cardiovascular disease (CVD)...
SGLT2 inhibitor empagliflozin may improve brain's insulin sensitivity in prediabetics: Study Medha Baranwal28 Dec 2021 10:00 AM ISTGermany: Researchers in a recent study published in Diabetes Care have shown for the first time that the SGLT2 inhibitor empagliflozin can be used for...
Pharmacological Treatment of Diabetes: ADA 2022 explores beyond metformin as initial therapy Dr. Prem Aggarwal24 Dec 2021 4:00 PM ISTNew Delhi: Metformin has been the cornerstone of Diabetes management for a long time. However, with the growing research in the field of diabetes and...
Empagliflozin retains benefits in 'True' HFpEF Patients Ruchika Sharma3 Dec 2021 5:31 PM ISTEmpagliflozin provides a wide range of benefits in patients with "true" heart failure and preserved ejection fraction (HFpEF) , meaning an LVEF of 50%...
Reluctance in SGLT-2 inhibitors usage Dr Umesh Khanna6 Oct 2021 4:16 PM ISTUnderstanding the reluctance in using SGLT2 inhibitors as drug of choice despite of its cardioprotective and renoprotective properties
Dapagliflozin relieves symptoms, physical limitations in HFpEF patients: PRESERVED-HF trial Medha Baranwal25 Sept 2021 9:00 AM ISTUSA: Dapagliflozin improves physical limitations and symptoms in patients having heart failure with preserved ejection fraction (HFpEF) within a...
SGLT-2 Inhibitors Increase Retinal Vein Occlusion Risk in Diabetics, Study Finds MD Bureau16 July 2021 9:00 AM ISTSGLT2 inhibitors are associated with an increased risk of RVO when compared with other glucose lowering drugs.
SGLT-2 Inhibitors may Improve Endothelial Function in T2D with CVD: Study Dr Kartikeya Kohli2 July 2021 9:00 AM ISTEmpagliflozin treatment has potential to improve endothelial function and has cardiovascular benefits, finds new study.
Canagliflozin use does not significantly reduce MI risk in diabetics: Study Medha Baranwal11 Jun 2021 9:00 AM ISTAustralia: The use of SGLT2 inhibitor canagliflozin does not significantly reduce the risk of myocardial infarction (MI) in the population of CANVAS...
